Akcea Therapeutics (NASDAQ:AKCA) changed 2.79% to recent value of $16.57. The stock transacted 174521 shares during most recent day however it has an average volume of 237.81K shares. It spotted trading -37.33% off 52-week high price. On the other end, the stock has been noted 107.12% away from the low price over the last 52-weeks.

On May 05, 2020, Akcea Therapeutics (NASDAQ:AKCA) a majority-owned affiliate of Ionis Pharmaceuticals, focused on developing and commercializing medicines to treat patients with serious and rare diseases, notified financial results for the first quarter ended March 31, 2020. The company reported a net loss for the first quarter ended March 31, 2020 on a GAAP basis of $43 million and on a non-GAAP basis of $36 million. Akcea had $421 million of cash, cash equivalents and short-term investments as of March 31, 2020.

This has been an exciting quarter with significant progress made across the company, said Damien McDevitt, chief executive officer of Akcea. With the two positive data readouts for AKCEA-ANGPTL3-LRx, which we are now referring to as vupanorsen, and AKCEA-APOCIII-LRx, and additions to our leadership team and board of directors, we have a solid foundation for the future. We are focused on the development and commercialization of medicines for serious and rare diseases, and are committed to bringing products to the rare disease patient community by utilizing a range of solutions to ensure the broadest reach. We generated $15 million in product sales from TEGSEDI and WAYLIVRA in the first quarter, as we continue to expand the number of countries where our products are commercially available, and ended the quarter with $421 million in cash, cash equivalents and short-term investments, putting us in a very strong position to execute on our strategic priorities in 2020 and beyond.

AKCA has a gross margin of 96.80% and an operating margin of 7.80% while its profit margin remained 8.30% for the last 12 months. Its earnings per share (EPS) expected to touch remained 115.80% for this year.

The company has 113.97M of outstanding shares and 16.95M shares were floated in the market. According to the most recent quarter its current ratio was 11.8 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.03% from the mean of 20 days, 8.27% from mean of 50 days SMA and performed -9.06% from mean of 200 days price. Company’s performance for the week was -4.88%, 13.88% for month and YTD performance remained -2.18%.